Paolo Tarantino shared a previous post of him on X and added:

“HER2 is about to change again.

In DESTINY-Breast06, Trastuzumab deruxtecan significantly improved PFS in chemo-naive patients with HER2-low and HER2-ultralow MBC. OS immature. Presented at ASCO.

Press Release on AstraZeneca.”

Quoting the previous post:

“In 2020 we proposed to add a HER2 Low slice to the HER2 pie chart, an addition that has now entered practice. But further changes await us in the coming years.

Excited to share our latest Cancer Discovery piece, outlining the present and future of HER2-low!”

Source: Paolo Tarantino/X

Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer. Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.

His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a robust publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field. Dr. Tarantino’s dedication and innovative approach contribute significantly to the advancement of breast cancer treatment and research.